{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:56:33Z","timestamp":1760885793967},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.lpm.2013.11.025","type":"journal-article","created":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T10:00:45Z","timestamp":1397642445000},"page":"637-644","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Gestion p\u00e9ri-op\u00e9ratoire des nouveaux anticoagulants oraux"],"prefix":"10.1016","volume":"43","author":[{"given":"Charles-Marc","family":"Samama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Pernod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Albaladejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2013.11.025_bib0005","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2013.11.025_bib0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1160\/TH12-03-0149","article-title":"Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation","volume":"108","author":"Lillo-Le Lou\u00ebt","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.11.025_bib0015","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","article-title":"Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding","volume":"119","author":"Warkentin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2013.11.025_bib0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.11.025_bib0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.11.025_bib0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.11.025_bib0035","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.11.025_bib0040","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.11.025_bib0045","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN-PE Investigators","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.lpm.2013.11.025_bib0050","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.acvd.2011.09.001","article-title":"Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis","volume":"104","author":"Si\u00e9","year":"2011","journal-title":"Arch Cardiovascular Dis"},{"key":"10.1016\/j.lpm.2013.11.025_bib0055","first-page":"269","article-title":"Chirurgies et actes invasifs chez les patients trait\u00e9s au long cours par un anticoagulant oral anti-IIa ou anti-Xadirect. Actualisation 2012","volume":"24","author":"Si\u00e9","year":"2012","journal-title":"STV"},{"key":"10.1016\/j.lpm.2013.11.025_bib0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.lpm.2013.11.025_bib0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.11.025_bib0070","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors","volume":"87","author":"Kaatz","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2013.11.025_bib0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.11.025_bib0080","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate","volume":"10","author":"Lambourne","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.11.025_bib0085","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.11.025_bib0090","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.ijcard.2013.07.152","article-title":"Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis","volume":"168","author":"Martin","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.lpm.2013.11.025_bib0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bjh.12620","article-title":"Activated prothrombin complex concentrate for dabigatran-associated bleeding","volume":"164","author":"Schulman","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2013.11.025_bib0100","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2013.11.025_bib0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.lpm.2013.11.025_bib0110","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2013.02.361","article-title":"Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose","volume":"62","author":"Chen","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2013.11.025_bib0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1160\/TH12-08-0573","article-title":"Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease","volume":"109","author":"Khadzhynov","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.11.025_bib0120","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.11.025_bib0125","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban\u2013an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"issue":"Suppl.\u00a06","key":"10.1016\/j.lpm.2013.11.025_bib0130","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.08-0673","article-title":"New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Weitz","year":"2008","journal-title":"Chest"},{"year":"2014","series-title":"Prise en charge des surdosages en antivitamines K, des situations \u00e0 risque h\u00e9morragique et des accidents h\u00e9morragiques chez les patients trait\u00e9s par antivitamines K en ville et en milieu hospitalier. Recommandations professionnelles","author":"Haute Autorit\u00e9 de sant\u00e9","key":"10.1016\/j.lpm.2013.11.025_bib0135"},{"key":"10.1016\/j.lpm.2013.11.025_bib0140","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.annfar.2013.04.016","article-title":"Prise en charge des complications h\u00e9morragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d\u2019int\u00e9r\u00eat en H\u00e9mostase P\u00e9riop\u00e9ratoire (GIHP) - mars 2013","volume":"32","author":"Pernod","year":"2013","journal-title":"Ann Fr Anesth Reanim"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214001389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498214001389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T22:24:08Z","timestamp":1538691848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498214001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0755498214001389"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2013.11.025","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gestion p\u00e9ri-op\u00e9ratoire des nouveaux anticoagulants oraux","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2013.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}